Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sanofi to take on lead Inhibrx candidate in $2.2bn deal

(Sharecast News) - Inhibrx announced an agreement with Sanofi on Tuesday, under which Sanofi subsidiary Aventis will acquire all assets and liabilities associated with INBRX-101, a recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently being trialled for alpha-1 antitrypsin deficiency (AATD) treatment. At the same time, non-101 assets and liabilities including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline, and corporate infrastructure, would form a new publicly-traded entity called Inhibrx Biosciences.

Under the deal, Sanofi would merge with Inhibrx, with each Inhibrx shareholder receiving $30.00 per share in cash, one contingent value right per share for a potential $5.00 cash payment upon a regulatory milestone, and one SEC-registered, publicly-listed share of the

new Inhibrx for every four shares of Inhibrx currently held.

Sanofi would also retire Inhibrx's outstanding third-party debt and fund the new Inhibrx with $200m in cash, while retaining an 8% equity interest.

The boards of both Inhibrx and Sanofi unanimously approved the transaction.

They said the total transaction value, combining the upfront cash portion, contingent value payment, and debt assumption, was estimated at $2.2bn.

Inhibrx shareholders would own 92% of the new Inhibrx, which would be capitalised with $200m in cash.

Following the merger, the new Inhibrx would continue to operate under the 'Inhibrx' name, with Mark Lappe serving as chairman and chief executive officer, along with the current management team.

Sanofi was intending to finance the acquisition using available cash resources, with completion contingent on the new Inhibrx spin-off transaction and customary closing conditions, including regulatory approvals and approval by Inhibrx's shareholders.

The transaction was expected to close in the second quarter of 2024.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Chipmaker TSMC lifts sales guidance as AI boom continues
(Sharecast News) - Apple and Nvidia supplier TSMC lifted its sales guidance for the full year on Thursday as demand for its chips continues to be supported by the ongoing AI boom.
Craneware full-year revenue set to top expectations
(Sharecast News) - US healthcare management and support specialist Craneware reported a strong full-year sales performance in an update on Thursday, driven by ongoing investment in the Trisus platform and successful partner programmes, resulting in significant returns for its US healthcare provider customers.
Meta reportedly in talks to buy stake in Ray-Ban maker EssilorLuxottica
(Sharecast News) - Facebook parent company Meta is reportedly in discussions to buy a 5% stake in Italian-French eyewear maker EssilorLuxottica as the social-media giant looks to deepen its ties with the company that makes its Ray-Ban Meta smart glasses.
Midwich revenue rises, earnings fall in first half
(Sharecast News) - Specialist audio-visual distributor Midwich Group reported a robust first-half revenue performance on Thursday, but a fall in earnings amid challenging market conditions.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.